UCB Australia Pty Ltd
Regulatory activities for this sponsor.
Loading...
Filters applied:Clear all
Sponsor content
10 result(s) found, displaying 1 to 10
-
Prescription medicine decision summaryZilbrysq (zilucoplan) has been approved as an add-on to standard therapy for the treatment of generalised myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Lacosamide
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment for Certolizumab pegol
-
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Brivaracetam
-
Australian Public Assessment Report (AusPAR)
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Certolizumab
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Rotigotine
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Certolizumab pegol